Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 10 04 2020
accepted: 26 05 2020
pubmed: 27 5 2020
medline: 3 7 2020
entrez: 27 5 2020
Statut: ppublish

Résumé

Long-term androgen deprivation therapy (ADT) negatively influences bone. The short-term effects on bone and mineral homeostasis are less known. Therefore, we aimed to investigate the early effects of ADT on calcium/phosphate homeostasis and bone turnover. Prospective cohort study. Eugonadal adult, male sex offenders, who were referred for ADT to the endocrine outpatient clinic, received cyproterone acetate. Changes in blood markers of calcium/phosphate homeostasis and bone turnover between baseline and first follow-up visit were studied. Of 26 screened patients, 17 were included. The median age was 44 (range 20-75) years. The median time interval between baseline and first follow-up was 13 (6-27) weeks. Compared to baseline, an 81% decrease was observed for median total testosterone (to 3.4 nmol/L (0.4-12.2); P < 0.0001) and free testosterone (to 0.06 nmol/L (0.01-0.18); P < 0.0001). Median total estradiol decreased by 71% (to 17.6 pmol/L (4.7-35.6); P < 0.0001). Increased serum calcium (P < 0.0001) and phosphate (P = 0.0016) was observed, paralleled by decreased PTH (P = 0.0156) and 1,25-dihydroxyvitamin D3 (P = 0.0134). The stable calcium isotope ratio (δ44/42Ca) decreased (P = 0.0458), indicating net calcium loss from bone. Bone-specific alkaline phosphatase and osteocalcin decreased (P < 0.0001 and P = 0.0056, respectively), periostin tended to decrease (P = 0.0500), whereas sclerostin increased (P < 0.0001), indicating suppressed bone formation. Serum bone resorption markers (TRAP, CTX) were unaltered. In adult men, calcium release from the skeleton occurs early following sex steroid deprivation, reflecting early bone resorption. The increase of sclerostin and reduction of bone formation markers, without changes in resorption markers, suggests a dominant negative effect on bone formation in the acute phase.

Identifiants

pubmed: 32454455
doi: 10.1530/EJE-20-0348
pii: EJE-20-0348
doi:
pii:

Substances chimiques

Androgen Antagonists 0
Phosphates 0
Testosterone 3XMK78S47O
Cyproterone Acetate 4KM2BN5JHF
Calcium SY7Q814VUP

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-189

Auteurs

Rougin Khalil (R)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Leen Antonio (L)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Michaël R Laurent (MR)

Center for Metabolic Bone Diseases, Geriatrics Department, University Hospitals Leuven, Leuven, Belgium.

Karel David (K)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Na Ri Kim (NR)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Pieter Evenepoel (P)

Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Anton Eisenhauer (A)

GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany.

Alexander Heuser (A)

GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany.

Etienne Cavalier (E)

Department of Clinical Chemistry, University of Liège (ULg CHU), Liège, Belgium.

Sundeep Khosla (S)

Kogod Center on Aging and Division of Endocrinology and Metabolism, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.

Frank Claessens (F)

Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Dirk Vanderschueren (D)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Brigitte Decallonne (B)

Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Aging, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH